GLP-1 Drugs List: The Plain-Language Guide

Quick answer: The GLP-1 family breaks into four practical groups: semaglutide (Ozempic for type 2 diabetes, Wegovy for weight management, Rybelsus as a daily pill), tirzepatide (Mounjaro for type 2, Zepbound for weight management — technically a dual GIP/GLP-1 agonist), liraglutide (Victoza for type 2, Saxenda for weight management — daily injection, older), and dulaglutide (Trulicity — weekly, type 2). All are prescription-only weekly injections except Rybelsus (pill) and the liraglutide pair (daily). What they’re approved for differs from what they’re famous for — and the choice between them is a prescriber conversation built on your glucose, weight, insurance, and supply reality.

The GLP-1 world generates more confusion per square inch than any corner of diabetes care — brand names, generic names, approvals, and a news cycle that outruns the labels. This is the plain-language map.

The family, grouped properly

Semaglutide (the most famous molecule)

• Ozempic — weekly injection, approved for type 2 diabetes (glucose control + proven cardiovascular risk reduction). Its weight-loss fame is real but technically off-label for the Ozempic brand.
• Wegovy — weekly injection, same molecule at higher doses, approved for chronic weight management (with obesity or overweight plus a weight-related condition).
• Rybelsus — the daily pill version of semaglutide, for type 2 diabetes. Same family, different route.

Tirzepatide (the dual agonist)

• Mounjaro — weekly injection, approved for type 2 diabetes. Technically a GIP + GLP-1 dual agonist — one extra hormone target, which is why head-to-head trials show it edging out semaglutide on glucose and weight.
• Zepbound — the higher-dose weight management version of tirzepatide.

Liraglutide (the older daily generation)

• Victoza — daily injection for type 2 diabetes; the grandfather of the modern class.
• Saxenda — daily injection approved for weight management.

Dulaglutide

• Trulicity — weekly injection for type 2 diabetes, with cardiovascular indication. Same class, different molecule, no weight-management brand.

The “related but different” name you’ll see

• Exenatide (Byetta/Bydureon) — an older GLP-1 agonist derived from lizard saliva (really); less used now, still exists in daily and weekly forms.

The questions that actually pick between them

Doctors choose based on things the internet rarely mentions:

• Glucose vs weight as the primary goal — Ozempic/Mounjaro for the former, Wegovy/Zepbound for the latter; same molecules, different doses and labels.
• Cardiovascular history — Ozempic, Trulicity, and Wegovy carry proven cardiovascular risk reduction indications; that matters enormously for people with heart disease history.
• Injection frequency tolerance — weekly (most) vs daily (liraglutide) vs daily pill (Rybelsus, which has its own absorption rules — empty stomach, waiting period before food).
• Supply reality — shortages have cycled through this class for years; availability sometimes decides before preference does.
• Coverage — insurers cover the diabetes-labeled versions differently from the weight-labeled ones, coupon programs notwithstanding.
• Tolerability — nausea is the class’s common denominator; dose escalation is deliberately slow, and some molecules are gentler than others for specific people.

The supply and cost reality (2026 edition)

No GLP-1 guide is honest without this section, because availability now shapes decisions as much as medicine does:

• Shortages cycle by molecule and dose. The lowest maintenance doses have repeatedly been the hardest to fill — ramp patients feel it first. Pharmacies and prescribers have workarounds (holding at an intermediate dose, switching molecules) — ask rather than assume.
• Coverage splits by label. The diabetes-labeled versions are covered far more broadly than the weight-labeled ones; manufacturer coupon programs exist for both but with different rules and expirations. The pharmacy’s answer to “what’s covered” is worth getting before the prescription is finalized, not after.
• Compounded versions are the gray zone. During shortages, compounding pharmacies produced “semaglutide” legally under specific rules — those products are not FDA-evaluated for quality the way brand products are, and the regulatory picture keeps shifting. If a deal online looks too good, that’s the category it lives in.
• The generic timeline matters. Semaglutide’s patent expiry is later this decade; prices will eventually follow the metformin path. Not a reason to wait — but a reason to be skeptical of lock-in style telehealth subscriptions.

None of this is medical advice — it’s the logistical layer that decides whether the medicine you and your prescriber chose actually arrives each month.

The history in three paragraphs (it explains the present)

The class’s origin story is one of pharmacology’s better ones: exendin-4, a peptide in Gila monster saliva, turned out to resemble human GLP-1 but last far longer in the body. Exenatide (Byetta, 2005) came from that discovery — the first GLP-1 agonist, twice-daily injections, modest glucose effects. Liraglutide (Victoza, 2010) followed with once-daily dosing.

The modern era arrived with semaglutide — a molecule engineered to survive for a week in the body, launching as Ozempic (2017) with weekly dosing and the cardiovascular trial results that changed the class’s reputation. Then the weight-management trials (STEP program) showed ~15% body weight loss — numbers previously achievable only with bariatric surgery — and Wegovy (2021) made the class a household name.

Tirzepatide pushed further: a dual GIP/GLP-1 agonist (Mounjaro, 2022) whose head-to-head data beat semaglutide on both glucose and weight. Zepbound (2023) brought the weight-management label. The shortage cycles and compounded-copycat wave that followed are a direct consequence — demand that outran manufacturing, which is why supply and coverage now shape prescribing as much as the molecules do.

Practical notes for anyone starting one

A few things worth knowing before the first pen:

• The dose ramp is the whole game. Every GLP-1 starts low and steps up monthly — the ramp exists to let your stomach adapt. Nausea that feels unmanageable is usually a ramp conversation, not a quit signal.
• Eating changes before the drug asks you to. Smaller portions, slower eating, and less fat at once will be more comfortable from week one — the dinner window approach matches how these drugs change appetite almost perfectly.
• Protein and strength training are not optional extras. Rapid appetite loss without resistance exercise is how muscle disappears; the patients who keep strength on these drugs train and eat protein deliberately.
• Sick-day and surgery instructions matter. These drugs slow digestion; anesthetic and illness protocols sometimes require pausing doses. Ask your prescriber for the specific rules rather than improvising.
• Keep the low blood sugar signs on your radar if you’re also on insulin or a sulfonylurea — combination therapy changes the risk profile, and prescribers usually lower those doses when adding the GLP-1.

What’s true class-wide

• They slow gastric emptying — which is why they work, and why our GLP-1 side-effects-adjacent guides emphasize smaller portions, slower eating, and the dinner window logic that matches how these drugs change appetite.
• They require food quality anyway. The drugs shrink appetite; nutrition decides whether the smaller amount of food is adequate. Muscle loss is the quiet risk — protein and strength training matter more on these drugs, not less.
• Hypoglycemia risk comes from combination, not the drug alone — GLP-1s alone rarely cause lows; combined with insulin or sulfonylureas they can (the doses usually get adjusted together). Our low blood sugar guide covers the signs.
• Compound “semaglutide” is not the same thing. Compounded versions flooded the market during shortages; they’re not FDA-evaluated the way brand products are, and the story around them keeps shifting. Buyer awareness is warranted.

Frequently asked questions

What are all the GLP-1 medications by name? The main ones: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound — a dual GIP/GLP-1), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon). All prescription-only.

Which GLP-1 is for diabetes and which is for weight loss? Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus are labeled for type 2 diabetes; Wegovy, Zepbound, and Saxenda are labeled for chronic weight management. The molecules overlap — labels and doses differ.

What’s the difference between Ozempic and Mounjaro? Different molecules: Ozempic is semaglutide (GLP-1 only), Mounjaro is tirzepatide (GIP + GLP-1 dual). Head-to-head trials favored tirzepatide for glucose and weight, but individual response, side effects, supply, and coverage decide real-world choices.

Is there a pill version of a GLP-1? Yes — Rybelsus, the daily oral form of semaglutide, for type 2 diabetes. It requires specific timing (empty stomach, with water, waiting before food or other medications).

Do GLP-1 drugs cause low blood sugar? By themselves, rarely — they work glucose-dependently. The risk appears in combination with insulin or sulfonylureas, which prescribers typically adjust when starting a GLP-1. Know the low blood sugar signs regardless.

This guide is also available in Spanish: Lista de medicamentos GLP-1: la guía en lenguaje llano.

Full Guide

Educational content only — not a substitute for advice from your doctor or pharmacist. Always work with your care team.